Muhammad Imtiaz Ahmad1, Michael D Shapiro2. 1. Department of Internal Medicine, Section on Hospital Medicine, Trinitas Regional Medical Center, 225 Williamson St, Elizabeth City, NJ, 07202, USA. imtiaz186@gmail.com. 2. Center for Prevention of Cardiovascular Disease, Section on Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Abstract
PURPOSE OF REVIEW: Cardiometabolic syndrome is characterized by abdominal adiposity, insulin resistance, hypertension, and dyslipidemia. There is a growing burden of cardiometabolic disease in many parts of the world. This review highlights the critical preventive and therapeutic measures that need to be implemented to reduce the impact of cardiometabolic syndrome on cardiovascular health. RECENT FINDINGS: Recent cardiovascular outcome trials demonstrated that newer glucose-lowering medications reduce cardiovascular and renal events in patients with type 2 diabetes mellitus (T2DM). These medications should be considered in patients with T2DM and atherosclerotic cardiovascular disease (ASCVD). These novel drugs may also play a role in primary prevention of cardiovascular disease (CVD) and renal disease in high-risk patients without T2DM. To manage dyslipidemia associated with cardiometabolic syndrome, in addition to lifestyle interventions and statin therapy, ezetimibe, and proprotein convertase subtilisin/Kexin type 9 (PCSK9), inhibitors can be used to reduce the risk of major adverse cardiovascular outcomes (MACE) especially in patients with T2DM and coronary artery disease (CAD). The residual risk of MACE in such a high-risk population can be further mitigated by treatment with an omega-3 fatty acid such as icosapent ethyl. Lifestyle modifications and the use of proven pharmacological therapies are essential for the prevention and progression of diabetes and ASCVD in those with the cardiometabolic syndrome.
PURPOSE OF REVIEW: Cardiometabolic syndrome is characterized by abdominal adiposity, insulin resistance, hypertension, and dyslipidemia. There is a growing burden of cardiometabolic disease in many parts of the world. This review highlights the critical preventive and therapeutic measures that need to be implemented to reduce the impact of cardiometabolic syndrome on cardiovascular health. RECENT FINDINGS: Recent cardiovascular outcome trials demonstrated that newer glucose-lowering medications reduce cardiovascular and renal events in patients with type 2 diabetes mellitus (T2DM). These medications should be considered in patients with T2DM and atherosclerotic cardiovascular disease (ASCVD). These novel drugs may also play a role in primary prevention of cardiovascular disease (CVD) and renal disease in high-risk patients without T2DM. To manage dyslipidemia associated with cardiometabolic syndrome, in addition to lifestyle interventions and statin therapy, ezetimibe, and proprotein convertase subtilisin/Kexin type 9 (PCSK9), inhibitors can be used to reduce the risk of major adverse cardiovascular outcomes (MACE) especially in patients with T2DM and coronary artery disease (CAD). The residual risk of MACE in such a high-risk population can be further mitigated by treatment with an omega-3 fatty acid such as icosapent ethyl. Lifestyle modifications and the use of proven pharmacological therapies are essential for the prevention and progression of diabetes and ASCVD in those with the cardiometabolic syndrome.
Authors: Francesco Cosentino; Peter J Grant; Victor Aboyans; Clifford J Bailey; Antonio Ceriello; Victoria Delgado; Massimo Federici; Gerasimos Filippatos; Diederick E Grobbee; Tina Birgitte Hansen; Heikki V Huikuri; Isabelle Johansson; Peter Jüni; Maddalena Lettino; Nikolaus Marx; Linda G Mellbin; Carl J Östgren; Bianca Rocca; Marco Roffi; Naveed Sattar; Petar M Seferović; Miguel Sousa-Uva; Paul Valensi; David C Wheeler Journal: Eur Heart J Date: 2020-01-07 Impact factor: 29.983
Authors: Miguel A Martínez-González; Ana Sánchez-Tainta; Dolores Corella; Jordi Salas-Salvadó; Emilio Ros; Fernando Arós; Enrique Gómez-Gracia; Miquel Fiol; Rosa M Lamuela-Raventós; Helmut Schröder; Jose Lapetra; Lluis Serra-Majem; Xavier Pinto; Valentina Ruiz-Gutierrez; Ramon Estruch Journal: Am J Clin Nutr Date: 2014-05-28 Impact factor: 7.045
Authors: K G M M Alberti; Robert H Eckel; Scott M Grundy; Paul Z Zimmet; James I Cleeman; Karen A Donato; Jean-Charles Fruchart; W Philip T James; Catherine M Loria; Sidney C Smith Journal: Circulation Date: 2009-10-05 Impact factor: 29.690
Authors: Ramón Estruch; Emilio Ros; Jordi Salas-Salvadó; Maria-Isabel Covas; Dolores Corella; Fernando Arós; Enrique Gómez-Gracia; Valentina Ruiz-Gutiérrez; Miquel Fiol; José Lapetra; Rosa M Lamuela-Raventos; Lluís Serra-Majem; Xavier Pintó; Josep Basora; Miguel A Muñoz; José V Sorlí; J Alfredo Martínez; Montserrat Fitó; Alfredo Gea; Miguel A Hernán; Miguel A Martínez-González Journal: N Engl J Med Date: 2018-06-13 Impact factor: 91.245
Authors: Gregory A Roth; Laura Dwyer-Lindgren; Amelia Bertozzi-Villa; Rebecca W Stubbs; Chloe Morozoff; Mohsen Naghavi; Ali H Mokdad; Christopher J L Murray Journal: JAMA Date: 2017-05-16 Impact factor: 56.272
Authors: Samuel Gonçalves Almeida da Encarnação; Pedro Flores; David Magalhães; Gil Afonso; Albino Pereira; Rui Brito Fonseca; Joana Ribeiro; Sandra Silva-Santos; José Eduardo Teixeira; António Miguel Monteiro; Ricardo Ferraz; Luís Branquinho; Pedro Forte Journal: Int J Environ Res Public Health Date: 2022-09-07 Impact factor: 4.614
Authors: Nicholas P Iskandar; Akshay J Reddy; Allen Dang; Muhammad S Ghauri; Mildred Min; Mark Bachir; Alex Bachir; Himanshu Wagh; Nathaniel Tak; Hetal Brahmbhatt Journal: Cureus Date: 2022-08-25